| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008515806-A |
| titleOfInvention |
Treatment and prevention of hypersensitivity and / or anaphylaxis with anti-IgE antibodies in patients undergoing replacement therapy |
| abstract |
The present invention relates generally to a method for the treatment and / or prevention of hypersensitivity, including anaphylaxis, in a patient who has been given a replacement therapy molecule that elicits an IgE-mediated response, the method comprising an anti-IgE antibody or a binding property thereof. It is a method by administering a fragment. Anti-IgE antibodies can inhibit IgE-mediated allergic reactions in mammals and also reduce the risk of anaphylactic reactions to replacement therapy molecules. Long-term administration of anti-IgE antibodies also down-regulates high affinity IgE receptors, further reducing the risk of hypersensitivity and / or anaphylaxis. This method may also reduce the dose and / or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668053-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10071114-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426451-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335395-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633422-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016517891-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11235057-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10434088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10420835-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298342-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019089784-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779641-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7134885-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10046064-B2 |
| priorityDate |
2004-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |